SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Efficacy of concurrent hyperbaric oxygen therapy with chemoradiotherapy for glioma: a meta-analysis.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to systematically evaluate the therapeutic efficacy and safety profile of concurrent hyperbaric oxygen therapy (HBOT) as an adjunct to chemoradiotherapy in patients with glioma.
methodsFollowing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive meta-analysis (PROSPERO registration: CRD420251007610). The search was performed in PubMed, Web of Science, Cochrane, EMBASE, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WanFang (inception to March 2025). Eligible studies were randomized controlled trials (RCTs) assessing tumor response, survival outcomes, quality of life (QoL), and adverse events. Subgroup analyses were performed based on HBOT pressure and session duration. Statistical analysis was performed using Review Manager version 5.3.
resultsNine RCTs involving 837 patients with glioma were included. Pooled analyses demonstrated that HBOT significantly enhanced objective tumor response rates (odds ratio [OR] = 3.67, 95% confidence interval [CI] 2.59-5.18; p < 0.00001) and 3 year overall survival (OR = 0.52, 95% CI 0.33-0.82; p = 0.005) when combined with chemoradiotherapy. QoL scores showed marked improvement in HBOT-treated groups (mean difference = 12.33, 95% CI 10.69-13.96; p < 0.00001). Subgroup analyses on tumor response demonstrated consistent benefits across HBOT pressures and durations.
conclusionThis meta-analysis provides evidence that concurrent HBOT with chemoradiotherapy may be associated with superior outcomes compared to chemoradiotherapy alone in glioma patients. These findings warrant verification in large-scale, multicenter Phase 3 trials.
Indexed as
Identifiers
41843266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.